ALLO
Allogene Therapeutics, Inc.
Biotechnology · Healthcare · United States
1.18
close · 2026-10-30
value
14
cheaper than peers14
quality
36
stronger fundamentals36
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.93× | 81 |
| cash flow yield, latest year | -36.7% | 33 |
| earnings yield, latest year | -73.7% | 26 |
| cash flow yield, 1 year ago | -49.3% | 26 |
| earnings yield, 3 years ago | -196.6% | 22 |
| cash flow yield, 2 years ago | -58.7% | 21 |
| earnings yield, 2 years ago | -177.1% | 20 |
| earnings yield, 1 year ago | -111.9% | 20 |
| cash flow yield, 3 years ago | -55.4% | 18 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -52.3% | 59 |
| operating margin | 0.0% | 50 |
| debt to equity | 29.1% | 22 |
3 of 4 measures available
Facts
| market cap | $408M |
| free cash flow | -$69.9M |
| employees | 150 |
| first trade | 2018-10-11 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-13 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.87 | -1.32 | -2.09 | -2.32 |
| free cash flow | -$149.6M | -$201.0M | -$239.2M | -$225.7M |
| net income | -$190.9M | -$257.6M | -$327.3M | -$340.4M |
| revenue | $0 | $22,000 | $95,000 | $156,000 |
| unusual items | -$2.4M | -$15.7M | -$13.2M | not reported |